HeXun Biosciences Co Ltd(TW:6986)
NT$37.50+0.20 (+0.54%)
TW:6986
HeXun Biosciences Co Ltd financials statements
NT$37.50
At close:+0.20 (+0.54%)
HeXun Biosciences Co Ltd (6986) Ratios
HeXun Biosciences Co Ltd Ratios
TW:6986's free cash flow for Q2 2026 was NT$34.46M. For the 2026 fiscal year, TW:6986's free cash flow was decreased by NT$-4.82M and operating cash flow was NT$39.29M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 25 | Dec 24 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 12.05 | 9.75 | 8.99 | 10.55 | 11.94 |
| Quick Ratio | 11.90 | 9.65 | 8.70 | 10.55 | 11.94 |
| Cash Ratio | 8.54 | 3.33 | 3.74 | 5.98 | 10.87 |
| Solvency Ratio | 0.55 | 1.48 | 1.99 | 0.11 | -0.39 |
| Operating Cash Flow Ratio | 1.43 | 2.62 | 2.25 | 0.56 | -4.54 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 80.20 | -60.37 |
| Net Current Asset Value | NT$ 265.60M | NT$ 514.14M | NT$ 396.91M | NT$ 121.96M | NT$ 13.54M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.12 | 0.04 | 0.05 | 0.17 | 0.25 |
| Debt-to-Equity Ratio | 0.15 | 0.05 | 0.06 | 0.22 | 0.35 |
| Debt-to-Capital Ratio | 0.13 | 0.05 | 0.05 | 0.18 | 0.26 |
| Long-Term Debt-to-Capital Ratio | 0.07 | 0.00 | 0.00 | 0.11 | 0.16 |
| Financial Leverage Ratio | 1.21 | 1.13 | 1.14 | 1.28 | 1.37 |
| Debt Service Coverage Ratio | 30.01 | 119.33 | 147.33 | 6.28 | -13.65 |
| Interest Coverage Ratio | 14.76 | 105.93 | 132.54 | -2.17 | -32.19 |
| Debt to Market Cap | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 |
| Interest Debt Per Share | 1.92 | 0.82 | 0.79 | 1.89 | 2.48 |
| Net Debt to EBITDA | -3.37 | -1.17 | -0.89 | -4.50 | 0.37 |
| Profitability Margins | |||||
| Gross Profit Margin | 87.10% | 83.61% | 91.01% | 90.18% | 0.00% |
| EBIT Margin | 27.07% | 40.24% | 56.79% | -7.17% | 0.00% |
| EBITDA Margin | 42.62% | 50.11% | 65.41% | 22.58% | 0.00% |
| Operating Profit Margin | 20.96% | 40.24% | 54.37% | -7.17% | 0.00% |
| Pretax Profit Margin | 25.65% | 42.95% | 56.38% | -10.49% | 0.00% |
| Net Profit Margin | 25.65% | 38.16% | 51.40% | -10.49% | 0.00% |
| Continuous Operations Profit Margin | 25.65% | 38.16% | 51.40% | -10.49% | 0.00% |
| Net Income Per EBT | 100.00% | 88.87% | 91.18% | 100.00% | 100.00% |
| EBT Per EBIT | 122.34% | 106.71% | 103.68% | 146.18% | 84.85% |
| Return on Assets (ROA) | 5.86% | 13.37% | 20.83% | -1.28% | -14.59% |
| Return on Equity (ROE) | 7.07% | 15.09% | 23.72% | -1.65% | -20.02% |
| Return on Capital Employed (ROCE) | 5.06% | 15.24% | 23.84% | -0.92% | -17.67% |
| Return on Invested Capital (ROIC) | 5.03% | 13.47% | 21.64% | -0.92% | -17.50% |
| Return on Tangible Assets | 6.23% | 13.71% | 21.64% | -1.43% | -14.68% |
| Earnings Yield | 1.38% | 3.86% | 4.74% | -0.15% | -1.56% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.86 | 3.93 | 3.38 | 9.93 | 0.00 |
| Payables Turnover | 3.38 | 15.17 | 6.07 | 0.89 | 0.00 |
| Inventory Turnover | 3.66 | 7.99 | 1.65 | 0.00 | 0.00 |
| Fixed Asset Turnover | 1.15 | 1.98 | 2.06 | 0.52 | 0.00 |
| Asset Turnover | 0.23 | 0.35 | 0.41 | 0.12 | 0.00 |
| Working Capital Turnover Ratio | 0.50 | 0.60 | 0.75 | 0.36 | 0.00 |
| Cash Conversion Cycle | 54.01 | 114.44 | 268.68 | -371.95 | 0.00 |
| Days of Sales Outstanding | 62.29 | 92.81 | 107.91 | 36.77 | 0.00 |
| Days of Inventory Outstanding | 99.69 | 45.68 | 220.87 | 0.00 | 0.00 |
| Days of Payables Outstanding | 107.97 | 24.05 | 60.09 | 408.72 | 0.00 |
| Operating Cycle | 161.98 | 138.49 | 328.78 | 36.77 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.15 | 3.56 | 2.63 | 0.30 | -1.16 |
| Free Cash Flow Per Share | 0.54 | 2.94 | 1.82 | 0.27 | -1.16 |
| Dividend Paid and CapEx Coverage Ratio | 1.89 | 5.68 | 3.24 | 9.15 | 0.00 |
| Capital Expenditure Coverage Ratio | 1.89 | 5.68 | 3.24 | 9.15 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.62 | 4.48 | 3.45 | 0.16 | -0.48 |
| Operating Cash Flow to Sales Ratio | 0.33 | 0.56 | 0.42 | 0.23 | 0.00 |
| Free Cash Flow Yield | 0.83% | 4.66% | 2.69% | 0.30% | -1.29% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 72.81 | 25.93 | 21.09 | -645.71 | -64.11 |
| Price-to-Sales (P/S) Ratio | 18.61 | 9.88 | 10.84 | 68.53 | 0.00 |
| Price-to-Book (P/B) Ratio | 5.13 | 3.91 | 5.00 | 10.77 | 12.84 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 119.84 | 21.46 | 37.13 | 338.98 | -77.69 |
| Price-to-Operating Cash Flow Ratio | 56.40 | 17.68 | 25.68 | 301.93 | -77.69 |
| Price-to-Earnings Growth (PEG) Ratio | -0.10 | -1.08 | 0.08 | 7.17 | 0.00 |
| Enterprise Value Multiple | 40.30 | 18.55 | 15.69 | 298.99 | -93.10 |
| Enterprise Value | 2.24B | 2.73B | 2.94B | 3.34B | 2.75B |
| EV to EBITDA | 40.30 | 18.55 | 15.69 | 298.99 | -93.10 |
| EV to Sales | 17.17 | 9.30 | 10.26 | 67.51 | 0.00 |
| EV to Free Cash Flow | 110.59 | 20.19 | 35.14 | 333.94 | -77.38 |
| EV to Operating Cash Flow | 52.04 | 16.64 | 24.31 | 297.45 | -77.38 |
| Tangible Book Value Per Share | 11.71 | 15.67 | 12.91 | 7.30 | 6.98 |
| Shareholders’ Equity Per Share | 12.62 | 16.12 | 13.49 | 8.40 | 7.04 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.11 | 0.09 | 0.00 | 0.00 |
| Revenue Per Share | 3.48 | 6.37 | 6.23 | 1.32 | 0.00 |
| Net Income Per Share | 0.89 | 2.43 | 3.20 | -0.14 | -1.41 |
| Tax Burden | 1.00 | 0.89 | 0.91 | 1.00 | 1.00 |
| Interest Burden | 0.95 | 1.07 | 0.99 | 1.46 | 1.04 |
| Research & Development to Revenue | 0.41 | 0.34 | 0.23 | 0.80 | 0.00 |
| SG&A to Revenue | 0.25 | 0.10 | 0.14 | 0.29 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.01 | 0.00 | 0.01 | 0.00 |
| Income Quality | 1.29 | 1.30 | 0.75 | -2.16 | 0.83 |
Currency in TWD
